--- title: "Mira Pharmaceuticals | 10-K: FY2025 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/281227316.md" datetime: "2026-03-31T18:05:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281227316.md) - [en](https://longbridge.com/en/news/281227316.md) - [zh-HK](https://longbridge.com/zh-HK/news/281227316.md) --- # Mira Pharmaceuticals | 10-K: FY2025 Revenue: USD 0 Revenue: As of FY2025, the actual value is USD 0. EPS: As of FY2025, the actual value is USD -1.35. EBIT: As of FY2025, the actual value is USD -10.59 M. MIRA Pharmaceuticals, Inc. operates as a single reportable and operating segment focused on the development and commercialization of pharmaceuticals targeting neurologic and neuropsychiatric disorders. #### Segment Revenue - The company did not generate any revenue from contracts with customers for the years ended December 31, 2025, or 2024. #### Operational Metrics - **Net Loss**: The net loss was - $10,442,485 for the year ended December 31, 2025, compared to - $7,852,659 for the year ended December 31, 2024. - **General and Administrative Expenses**: These expenses increased to $8,773,329 in 2025 from $4,712,753 in 2024, primarily due to increased stock-based compensation and payroll-related expenses. - **Research and Development Expenses**: These expenses decreased to $1,719,783 in 2025 from $3,305,575 in 2024, primarily due to decreased development costs for MIRA-55. - **Total Operating Costs**: Total operating costs were $10,493,112 in 2025, up from $8,018,328 in 2024. - **Interest Income**: Interest income was $98,911 in 2025, down from $165,669 in 2024. - **Other Expense**: The company reported an other expense of - $13,072 in 2025, with no comparable expense in 2024. - **Unrealized Loss on Short-Term Investment**: An unrealized loss of - $35,212 was recorded in 2025, with no comparable loss in 2024. - **Total Other Income, Net**: Total other income, net, was $50,627 in 2025, a decrease from $165,669 in 2024. - **Net Loss Attributable to Common Stockholders**: This was - $31,999,306 in 2025, which includes a deemed dividend of - $21,556,821, compared to - $7,852,659 in 2024. - **Basic and Diluted Loss Per Share**: The loss per share was - $1.35 in 2025, compared to - $0.51 in 2024. - **Basic Weighted Average Common Stock Shares Outstanding**: This increased to 23,694,333 shares in 2025 from 15,444,149 shares in 2024. - **Accumulated Deficit**: The accumulated deficit reached approximately - $39.6 million as of December 31, 2025, up from - $29.1 million as of December 31, 2024. - **Stockholders’ Equity**: Total stockholders’ equity was approximately $10.4 million at December 31, 2025, compared to approximately $2.2 million at December 31, 2024. - **Working Capital**: Working capital was approximately $10.4 million at December 31, 2025, compared to $2.2 million at December 31, 2024. #### Cash Flow - **Net Cash Used in Operating Activities**: Cash used in operating activities was - $4.7 million for the year ended December 31, 2025, an improvement from - $5.6 million for the year ended December 31, 2024. - **Net Cash Provided by Financing Activities**: Cash provided by financing activities was $8.2 million in 2025, including $7.0 million from common stock sales (net of - $0.3 million in offering costs), $0.9 million from stock option exercises, and $0.6 million from a related party. This compares to $3.8 million in 2024, including $3.6 million from common stock sales (net of - $0.13 million in offering costs) and $0.1 million from a related party disgorgement. - **Net Change in Cash**: The net change in cash was an increase of $3,513,930 in 2025, contrasting with a decrease of - $1,769,635 in 2024. - **Cash and Cash Equivalents**: The company had approximately $6.3 million in cash and cash equivalents as of December 31, 2025, compared to $2.8 million at December 31, 2024. #### Unique Metrics - **ATM Financings**: MIRA Pharmaceuticals, Inc. raised $6.7 million and $3.6 million from At The Market (ATM) financings for the years ended December 31, 2025, and 2024, respectively. - **Short-Term Investment**: As of December 31, 2025, the company held a short-term investment, at fair value, of $4,683,099, which was acquired as part of the SKNY Pharmaceuticals acquisition. #### Outlook / Guidance MIRA Pharmaceuticals, Inc. expects its cash and cash equivalents to be sufficient to fund operations, development plans, and capital expenditures into at least the first quarter of 2027. The company plans to secure additional capital through public or private equity offerings and strategic transactions to alleviate going concern doubts. However, there is no assurance that MIRA Pharmaceuticals, Inc. will obtain sufficient funding on acceptable terms or achieve profitability. ### Related Stocks - [MIRA.US](https://longbridge.com/en/quote/MIRA.US.md) ## Related News & Research - [MIRA highlights SKNY-1 preclinical data in new publication](https://longbridge.com/en/news/286256663.md) - [MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results](https://longbridge.com/en/news/286319406.md) - [POMDOCTOR LIMITED Announces Fiscal Year 2025 Financial Results | POM Stock News](https://longbridge.com/en/news/286463818.md) - [Kolibri (KGEI) Q4 2025 Earnings Call Transcript](https://longbridge.com/en/news/287108015.md) - [Bristow Spotlights Advanced Air Mobility Milestones and Safety Performance in 2025 Sustainability Report | VTOL Stock News](https://longbridge.com/en/news/286912514.md)